BibTex RIS Cite

Matriks metalloproteinazlar: diş dokuları ve çürük üzerine etkileri

Year 2011, Volume: 14 Issue: 3, 246 - 257, 23.09.2011

Hande Erkli Engin Ersöz

Abstract

ÖZET

Oral kavitede görülen hastalıkların mikroorganizmalarla olan ilişkileri ortaya konduktan sonra tedavi seçenekleri bu organizmaları ortadan kaldırmaya yönelik olmuştur. Ancak günümüzde yapılan çalışmalar bu hastalıkların oluşmalarının yalnızca mikroorganizmalar nedeniyle olmadığını aynı zamanda konak cevabının ve konak kaynaklı faktörlerin de hastalığın oluşması ve seyrini etkilediğini gözler önüne sermiştir. Bu konak kaynaklı faktörlerden bir tanesi ise Matriks Metallo Proteinaz (MMP) adı verilen bir enzim grubudur. MMP'ler; yıkımdan sorumlu birçok ekstraselüler matriks proteini ile organogenez, büyüme ve doku dönüşümü sırasında uyum içinde çalışan enzim grubudur. Bu derleme matriks metalloproteinazlarının hem sistemik etkilerine değinecek hem de ağız hastalıklarının seyri ve tedavi seçenekleri içerisinde üstlenebilecekleri rollere ışık tutacak şekilde hazırlanmıştır.

Anahtar kelimeler: Matriks metalloproteinaz, çürük, kollagen, matriks metalloproteinaz doku inhibitörü.

ABSTRACT

Since relationship between oral diseases and microorganisms have been revealed treatment options were focused to terminate those microorganisms. However; today's researches show that host response and host related factors have influence on diseases and their progress. Matrix metalloproteinases (MMP) are one of those host related factors. MMP's act as a degradative extracelular matrix protein during organogenesis, growth and tissue transformation processes. This review is about; systemic effects of MMP's and their roles in disease progression and treatment options.

Key words: Matrix metalloproteinases, caries, kollagen, tissue inhibitors of matrix metalloproteinases.

 

Keywords

-

References

  • 1. Sorsa T, Tjaderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004;10:311–318.
  • 2. Katz S, Park KK, Palenick CJ. In vitro root surface caries studies. J Oral Med 1987;42:40-48.
  • 3. van Strijp AJ, van Steenbergen TJ, de Graaff J, ten Cate JM. Bacterial colonization and degradation of demineralized dentin matrix in situ. Caries Res 1994;28:21-27.
  • 4. Armstrong WG. Further studies on the action of collagenase on sound and carious human dentin. J Dent Res 1958;37:1001-1015.
  • 5. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-214.
  • 6. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993;64:474-484.
  • 7. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
  • 8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
  • 9. Sognnaes RF. Introduction to the problem of caries. Ann NY Acad Sci 1965;131:687-689.
  • 10. Tjäderhane L, Larjava H, Sorsa T, Uitto VJ, Larmas M, Salo T. The activation and function of host matrix metalloproteinases in dentin matrix breakdown in caries lesions. J Dent Res 1998;77:1622-1629.
  • 11. Uitto VJ, Overall CM, McCulloch C. Proteolytic host enzymes in gingival crevice fluid. Periodontology 2003;31:77–104.
  • 12. Bauer EA, Stricklin GP, Jeffrey JJ, Eisen AZ. Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 1975;64:232- 240. Cumhuriyet Dent J 2011;14(3):246-257 252 E
  • 13. Woolley DE, Roberts DR, Evanson JM. Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem Biophys Res Commun 1975;66:747-754.
  • 14. Chang YC, Yang SF, Lai CC, Liu JY, Hsieh YS. Regulation of matrix metalloproteinase production by cytokines, pharmacological agents and periodontal pathogens in human periodontal ligament fibroblast cultures. J Periodontal Res 2002;37:196-203.
  • 15. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003;12:109-125.
  • 16. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
  • 17. Snoek-van Beurden PAM, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005;38:73-83.
  • 18. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)- 1 and TIMP-2. J Biol Chem 1997;272:29975-29983.
  • 19. English WR, Velasco G, Stracke JO, Knäuper V, Murphy G. Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett 2001;491:137-142.
  • 20. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-3727.
  • 21. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growthpromoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide-range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
  • 22. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-2379.
  • 23. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-244.
  • 24. Würtz SØ, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 2005;4:483-491.
  • 25. Würtz SØ, Schrohl AS, Sørensen NM, Lademann U, Christensen IJ, Mouridsen H, Brünner N. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215-227.
  • 26. Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004;324:440-445.
  • 27. Guedez L, Courtemanch L, StetlerStevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-1349.
  • 28. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-2010.
  • 29. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-6275.
  • 30. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246- 253.
  • 31. Jones SE, Jomary C, Neal MJ. Expression of TIMP3 mRNA is elevated in retinas affected by simplex retinitis pigmentosa. FEBS Lett 1994;352:171-174.
  • 32. Jomary C, Neal MJ, Jones SE. Increased expression of retinal TIMP3 mRNA in simplex retinitis pigmentosa is localized to photoreceptorretaining regions. J Neurochem 1995;64:2370- 2373.
  • 33. Schwartz SB, Aleman TS, Cideciyan AV, Swaroop A, Jacobson SG, Stone EM. De novo mutation in the RP1 gene (Arg677ter) associated with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2003;44:3593- 3597.
  • 34. Verstappen J, Von den Hoff JW. Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease. J Dent Res 2006;85:1074-1084.
  • 35. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL- 10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995;96:2304-2310.
  • 36. Osman M, Tortorella M, Londei M, Quaratino S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology 2002;105:73-82.
  • 37. Kouwenhoven M, Ozenci V, Tjernlund A, Pashenkov M, Homman M, Press R, Link H. Monocytederived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J Neuroimmunol 2002;126:161-171.
  • 38. Caterina JJ, Skobe Z, Shi J, Ding Y, Simmer JP, Birkedal-Hansen H, Bartlett JD. Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 2002; 277: 49598-49604.
  • 39. Bartlett JD, Beniash E, Lee DH, Smith CE. Decreased mineral content in MMP-20 null mouse enamel is prominent during the maturation stage. J Dent Res 2004;83:909-913.
  • 40. Sulkala M, Larmas M, Sorsa T, Salo T, Tja¨derhane L. The localization of matrix metalloproteinase-20 (MMP- 20, Enamelysin) in mature human teeth. J Dent Res 2002;81:603-607.
  • 41. Caron C, Xue J, Sun X, Simmer JP, Barlett JD. Gelatinase A (MMP-2) in developing tooth tissues and amelogenin hydrolysis. J Dent Res 2001;80:1660-1664.
  • 42. Hannas AR, Pereira JC, Granjeiro JM, Tjäderhane L. The role of matrix metalloproteinases in the oral environment. Acta Odontol Scand. 2007;65:1-13.
  • 43. Fejerskov O, Thylstrup A, Larsen MJ. Clinical and structural features and possible pathogenic mechanisms of dental fluorosis. Scand J Dent Res 1977;85:510-534.
  • 44. DenBesten PK, Yan Y, Featherstone JDB, Hilton JF, Smith CE, Li W. Effects of fluoride on rat dental enamel matrix proteinases. Arch Oral Biol 2002;47:763-770.
  • 45. Dayan D, Binderman I, Mechanic GL. A preliminary study of activation of collagenase in carious human dentine matrix. Arch Oral Biol 1983;28:185- 187.
  • 46. Martin de Las Heras S, Valenzuela A, Overall CM. The matrix metalloproteinase gelatinase A in human dentine. Arch Oral Biol 2000;45:757-765.
  • 47. Sulkala M, Tervahartiala T, Sorsa T, Larmas M, Salo T, Tjäderhane L. Matrix metalloproteinase-8 (MMP-8) is the major collagenase in human dentin. Arch Oral Biol 2007;52:121- 127.
  • 48. Keltjens HM, Schaeken MJ, Van Der Hoeven JS, Hendriks JC. Microflora of plaque from sound and carious root surfaces. Caries Res 1987;21:193-199.
  • 49. Jackson RJ, Lim DV, Dao ML. Identification and analysis of a collagenolytic activity in Streptococcus mutans. Curr Microbiol 1997;34:49-54.
  • 50. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase_/ gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995;72:311-322.
  • 51. Kawasaki K, Featherstone JDB. Effects of collagenase on root demineralization. J Dent Res 1997;76: 588-595.
  • 52. Pashley DH, Tay FR, Yiu C, Hashimoto M, Carvalho RM, Ito S. Collagen degradation by host-derived enzymes during aging. J Dent Res 2004;83:216-221.
  • 53. Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996;23:1127-1132.
  • 54. Vuotila T, Ylikontiola L, Sorsa T, Luoto H, Hanemaaijer R, Salo T, Tjäderhane L. The relationship between MMPs and pH in whole saliva of irradiated head and neck cancer patients. J Oral Pathol Med 2002;31:329-338.
  • 55. Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, Xu JW, Manthorpe R, Whittington J, Larsson A, Salo T, Kjeldsen L, Stenman UH, Eisen AZ. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren’s syndrome. Matrix Biol 1998;17:/335-347.
  • 56. Lauhio A, Salo T, Tjäderhane L, Lahdevirta J, Golub LM, Sorsa T. Tetracyclines in treatment of rheumatoid arthritis. Lancet 1995;346:645-646.
  • 57. Sulkala M, Wahlgren J, Larmas M, Sorsa T, Teronen O, Salo T, Tjäderhane L. The effects of MMP inhibitors on human salivary MMP activity and caries progression in rats. J Dent Res 2001; 80: 1545-1549.
  • 58. Gendron R, Greiner D, Sorsa T, Maryrand D. Inhibition of the activities of matrix metalloproteinases 2, 8 and 9 by chlorexidine. Clin Diagn Lab Immunol 1999;6:437-439.
  • 59. Van Strijp AJP, Jansen DC, Degroot J, Ten Cate JM, Everts V. Host-derived proteinases and degradation of dentin collagen in situ. Caries Res 2003;37:58-65.
  • 60. De Munck J, Van Meerbeek B, Yoshida Y, Inoue S, Vargas M, Suzuki K, Lambrechts P, Vanherle G. Four-year water degradation of total etch adhesives bonded to dentin. J Dent Res 2003;82:136-140.
  • 61. Hashimoto M, Tay FR, Ohno H, Sano H, Kaga M, Yiu C, Kumagai H, Kudou Y, Kubota M, Oguchi H. SEM and TEM analysis of water degradation of human dentinal collagen. J Biomed Mater Res 2003;66:287-298.
  • 62. Carrilho MRO, Tay FR, Pashley DH, Tjäderhane L, Carvalho RM. Mechanical stability of resin-dentin bond components. Dent Mater 2005;21:232-241.
  • 63. Hebling J, Pashley DH, Tjaderhane L, Tay FR. Chlorhexidine arrests subclinical degradation of dentin hybrid layers in vivo. J Dent Res 2005;84:741-746.
  • 64. Van Meerbeek B, De Munck J, Yoshida Y, Inoue S, Vargas M, Vijay P, Van Landuyt K, Lambrechts P, Vanherle G. Buonocore memorial lecture. Adhesion to enamel and dentin: current status and future challenges. Oper Dent 2003;28:215- 235.
  • 65. De Munck J, Van Landuyt K, Peumans M, Poitevin A, Lambrechts P, Braem M, Van Meerbeek B. A critical review of the durability of adhesion to tooth tissue: methods and results. J Dent Res 2005;84:118-132.
  • 66. Breschi L, Mazzoni A, Ruggeri A, Cadenaro M, Di Lenarda R, De Stefano Dorigo E. Dental adhesion review: aging and stability of the bonded interface. Dent Mater 2008;24:90-101.
  • 67. Tay FR, Pashley DH, Loushine RJ, Weller RN, Monticelli F, Osorio R. Self-etching adhesives increase collagenolytic activity in radicular dentin. J Endod 2006;32:862-868.
  • 68. Carrilho MR, Geraldeli S, Tay F, de Goes MF, Carvalho RM, Tjäderhane L, Reis AF, Hebling J, Mazzoni A, Breschi L, Pashley D. In vivo preservation of the hybrid layer by chlorhexidine. J Dent Res 2007;86:529-533.
  • 69. Koshiro K, Inoue S, Tanaka T, Koase K, Fujita M, Hashimoto M, Sano H. In vivo degradation of resin-dentin bonds produced by a self-etch vs. a total-etch adhesive system. Eur J Oral Sci 2004;112:368-375.
  • 70. Mazzoni A, Pashley DH, Nishitani Y, Breschi L, Mannello F, Tjäderhane L, Toledano M, Pashley EL, Tay FR. Reactivation of inactivated endogenous proteolytic activities in phosphoric acid-etched dentine by etch-and-rinse adhesives. Biomaterials 2006;27:4470-4476.
  • 71. Nishitani Y, Yoshiyama M, Wadgaonkar B, Breschi L, Mannello F, Mazzoni A, Carvalho RM, Tjäderhane L, Tay FR, Pashley DH. Activation of gelatinolytic/ collagenolytic activity in dentin by self-etching adhesives. Eur J Oral Sci 2006;114:160-166.
  • 72. Mazzoni A, Mannello F, Tay FR, Tonti GAM, Papa S, Mazotti G, Di Lenarda R, Pashley DH, Breschi L. Zymographic analysis and characterization of MMP-2 and -9 forms in human sound dentin. J Dent Res 2007;86:436-440.
  • 73. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
  • 74. Overall CM, Lopez-Otín C. Strategies for MMP inhibition in cancer: innovations for the posttrial era. Nat Rev Cancer 2002;2:657-672.
  • 75. Santos M, De Souza A, Gerlach R, Trevılatto P, Scarel-Camınaga R, Lıne S. Inhibition of human pulpal gelatinases (MMP-2 and MMP-9) by zinc oxide cements. J Oral Rehabil 2004;31;660–664.
  • 76. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub ML, Vernillo AT. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. J Periodontol 2002;73:726-734.
  • 77. Kivela-Rajamaki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, Salo T, Sorsa T. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003;38:583-590
  • 78. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
  • 79. Tjäderhane L, Sulkala M, Sorsa T, Teronen O, Larmas M, Salo T. The effect of MMP inhibitor metastat on fissure caries progression in rats. Ann NY Acad Sci 1999;878:686-688.
  • 80. Huet E, Cauchard JH, Berton A, Robinet A, Decarme M, Hornebeck W, Bellon G. Inhibition of plasminmediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5. Biochem Pharmacol 2004;67:643-654.
  • 81. Demeule M, Brossard M, Page M, Gingras D, Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 2000;1478:51-60.
  • 82. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001;91:822-832.
  • 83. Sartor L, Pezzato E, Dell'Aica I, Caniato R, Biggin S, Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. Biochem Pharmacol 2002;64:229-237.
  • 84. Stanley A, Wilson M, Newman HN. The in vitro effects of chlorhexidine on subgingival plaque bacteria. J Clin Periodontol 1989;16:259–264.
  • 85. Jolkovsky DL, Waki MY, Newman MG, Otomo-Corgel J, Madison M, Flemming TF, Nachnani S, Nowzari H. Clinical and microbiological effects of subgingival and gingival marginal irrigation with chlorhexidine gluconate. J Periodontol 1990;61:663– 669.
  • 86. Wieder, SG, Newman HN, Strahan JD. Stannous fluoride and subgingival chlorhexidine irrigation in the control of plaque and chronic periodontitis. J Clin Periodontol 1983;10:172–181.
  • 87. Lee W, Aitken S, Sodek J, McCulloch C. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: a role of active enzyme in human periodontitis. J Periodontal Res 1995;30:23–33.
  • 88. Rifkin, BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissuedestructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 1993;64:819–827.
  • 89. Hashimoto M, Ohno H, Sano H, Kaga M, Oguchi H. In vitro degradation of resin-dentin bonds analyzed by microtensile bond test, scanning and transmission electron microscopy. Biomaterials 2003;24:3795-3805.
  • 90. Ferrari M, Mason PN, Goracci C, Pashley DH, Tay FR. Collagen degradation in endodontically treated teeth after clinical function. J Dent Res 2004;83:414-419.
  • 91. Yoshida E, Hashimoto M, Hori M, Kaga M, Sano H, Oguchi H. Deproteinizing effects on resin-tooth bond structures. J Biomed Mater Res B Appl Biomater 2004;68:29-35.
  • 92. Armstrong SR, Vargas MA, Chung I, Pashley DH, Campbell JA, Laffoon JE, Qian F. Resin-dentin interfacial ultrastructure and microtensile dentin bond strength after five-year water storage. Oper Dent 2004;29:705-712.

Matriks metalloproteinazlar: diş dokuları ve çürük üzerine etkileri

Year 2011, Volume: 14 Issue: 3, 246 - 257, 23.09.2011

Hande Erkli Engin Ersöz

Abstract

Oral kavitede görülen hastalıkların mikroorganizmalarla konduktan organizmaları ortadan kaldırmaya yönelik olmuştur. Ancak hastalıkların mikroorganizmalar nedeniyle olmadığını aynı zamanda konak cevabının ve konak kaynaklı faktörlerin de hastalığın oluşması ve seyrini etkilediğini gözler önüne sermiştir. Bu konak kaynaklı faktörlerden bir tanesi ise Matriks Metallo Proteinaz (MMP) adı verilen bir enzim grubudur. MMP'ler; yıkımdan sorumlu birçok ekstraselüler matriks proteini ile organogenez, büyüme ve doku dönüşümü sırasında uyum içinde çalışan enzim grubudur. metalloproteinazlarının hem sistemik etkilerine değinecek hem de ağız hastalıklarının seyri ve tedavi seçenekleri içerisinde üstlenebilecekleri rollere ışık tutacak şekilde hazırlanmıştır

Keywords

Matriks metalloproteinaz çürük kollagen matriks metalloproteinaz doku inhibitörü

References

  • 1. Sorsa T, Tjaderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral diseases. Oral Dis 2004;10:311–318.
  • 2. Katz S, Park KK, Palenick CJ. In vitro root surface caries studies. J Oral Med 1987;42:40-48.
  • 3. van Strijp AJ, van Steenbergen TJ, de Graaff J, ten Cate JM. Bacterial colonization and degradation of demineralized dentin matrix in situ. Caries Res 1994;28:21-27.
  • 4. Armstrong WG. Further studies on the action of collagenase on sound and carious human dentin. J Dent Res 1958;37:1001-1015.
  • 5. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-214.
  • 6. Birkedal-Hansen H. Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 1993;64:474-484.
  • 7. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274:21491-21494.
  • 8. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-839.
  • 9. Sognnaes RF. Introduction to the problem of caries. Ann NY Acad Sci 1965;131:687-689.
  • 10. Tjäderhane L, Larjava H, Sorsa T, Uitto VJ, Larmas M, Salo T. The activation and function of host matrix metalloproteinases in dentin matrix breakdown in caries lesions. J Dent Res 1998;77:1622-1629.
  • 11. Uitto VJ, Overall CM, McCulloch C. Proteolytic host enzymes in gingival crevice fluid. Periodontology 2003;31:77–104.
  • 12. Bauer EA, Stricklin GP, Jeffrey JJ, Eisen AZ. Collagenase production by human skin fibroblasts. Biochem Biophys Res Commun 1975;64:232- 240. Cumhuriyet Dent J 2011;14(3):246-257 252 E
  • 13. Woolley DE, Roberts DR, Evanson JM. Inhibition of human collagenase activity by a small molecular weight serum protein. Biochem Biophys Res Commun 1975;66:747-754.
  • 14. Chang YC, Yang SF, Lai CC, Liu JY, Hsieh YS. Regulation of matrix metalloproteinase production by cytokines, pharmacological agents and periodontal pathogens in human periodontal ligament fibroblast cultures. J Periodontal Res 2002;37:196-203.
  • 15. Kerkelä E, Saarialho-Kere U. Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer. Exp Dermatol 2003;12:109-125.
  • 16. Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004;49:187-198.
  • 17. Snoek-van Beurden PAM, Von den Hoff JW. Zymographic techniques for the analysis of matrix metalloproteinases and their inhibitors. Biotechniques 2005;38:73-83.
  • 18. Olson MW, Gervasi DC, Mobashery S, Fridman R. Kinetic analysis of the binding of human matrix metalloproteinase-2 and -9 to tissue inhibitor of metalloproteinase (TIMP)- 1 and TIMP-2. J Biol Chem 1997;272:29975-29983.
  • 19. English WR, Velasco G, Stracke JO, Knäuper V, Murphy G. Catalytic activities of membrane-type 6 matrix metalloproteinase (MMP25). FEBS Lett 2001;491:137-142.
  • 20. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-3727.
  • 21. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growthpromoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide-range of cells. A possible new growth factor in serum. FEBS Lett 1992;298:29-32.
  • 22. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:2373-2379.
  • 23. Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999;54:235-244.
  • 24. Würtz SØ, Christensen IJ, Schrohl AS, Mouridsen H, Lademann U, Jensen V. Measurement of the uncomplexed fraction of tissue inhibitor of metalloproteinases-1 in the prognostic evaluation of primary breast cancer patients. Mol Cell Proteomics 2005;4:483-491.
  • 25. Würtz SØ, Schrohl AS, Sørensen NM, Lademann U, Christensen IJ, Mouridsen H, Brünner N. Tissue inhibitor of metalloproteinases-1 in breast cancer. Endocr Relat Cancer 2005;12:215-227.
  • 26. Akahane T, Akahane M, Shah A, Thorgeirsson UP. TIMP-1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004;324:440-445.
  • 27. Guedez L, Courtemanch L, StetlerStevenson M. Tissue inhibitor of metalloproteinase (TIMP)-1 induces differentiation and an antiapoptotic phenotype in germinal center B cells. Blood 1998;92:1342-1349.
  • 28. Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A, et al. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998;102:2002-2010.
  • 29. Li G, Fridman R, Kim HR. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999;59:6267-6275.
  • 30. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, et al. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998;75:246- 253.
  • 31. Jones SE, Jomary C, Neal MJ. Expression of TIMP3 mRNA is elevated in retinas affected by simplex retinitis pigmentosa. FEBS Lett 1994;352:171-174.
  • 32. Jomary C, Neal MJ, Jones SE. Increased expression of retinal TIMP3 mRNA in simplex retinitis pigmentosa is localized to photoreceptorretaining regions. J Neurochem 1995;64:2370- 2373.
  • 33. Schwartz SB, Aleman TS, Cideciyan AV, Swaroop A, Jacobson SG, Stone EM. De novo mutation in the RP1 gene (Arg677ter) associated with retinitis pigmentosa. Invest Ophthalmol Vis Sci 2003;44:3593- 3597.
  • 34. Verstappen J, Von den Hoff JW. Tissue Inhibitors of Metalloproteinases (TIMPs): Their Biological Functions and Involvement in Oral Disease. J Dent Res 2006;85:1074-1084.
  • 35. Lacraz S, Nicod LP, Chicheportiche R, Welgus HG, Dayer JM. IL- 10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995;96:2304-2310.
  • 36. Osman M, Tortorella M, Londei M, Quaratino S. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases define the migratory characteristics of human monocyte-derived dendritic cells. Immunology 2002;105:73-82.
  • 37. Kouwenhoven M, Ozenci V, Tjernlund A, Pashenkov M, Homman M, Press R, Link H. Monocytederived dendritic cells express and secrete matrix-degrading metalloproteinases and their inhibitors and are imbalanced in multiple sclerosis. J Neuroimmunol 2002;126:161-171.
  • 38. Caterina JJ, Skobe Z, Shi J, Ding Y, Simmer JP, Birkedal-Hansen H, Bartlett JD. Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem 2002; 277: 49598-49604.
  • 39. Bartlett JD, Beniash E, Lee DH, Smith CE. Decreased mineral content in MMP-20 null mouse enamel is prominent during the maturation stage. J Dent Res 2004;83:909-913.
  • 40. Sulkala M, Larmas M, Sorsa T, Salo T, Tja¨derhane L. The localization of matrix metalloproteinase-20 (MMP- 20, Enamelysin) in mature human teeth. J Dent Res 2002;81:603-607.
  • 41. Caron C, Xue J, Sun X, Simmer JP, Barlett JD. Gelatinase A (MMP-2) in developing tooth tissues and amelogenin hydrolysis. J Dent Res 2001;80:1660-1664.
  • 42. Hannas AR, Pereira JC, Granjeiro JM, Tjäderhane L. The role of matrix metalloproteinases in the oral environment. Acta Odontol Scand. 2007;65:1-13.
  • 43. Fejerskov O, Thylstrup A, Larsen MJ. Clinical and structural features and possible pathogenic mechanisms of dental fluorosis. Scand J Dent Res 1977;85:510-534.
  • 44. DenBesten PK, Yan Y, Featherstone JDB, Hilton JF, Smith CE, Li W. Effects of fluoride on rat dental enamel matrix proteinases. Arch Oral Biol 2002;47:763-770.
  • 45. Dayan D, Binderman I, Mechanic GL. A preliminary study of activation of collagenase in carious human dentine matrix. Arch Oral Biol 1983;28:185- 187.
  • 46. Martin de Las Heras S, Valenzuela A, Overall CM. The matrix metalloproteinase gelatinase A in human dentine. Arch Oral Biol 2000;45:757-765.
  • 47. Sulkala M, Tervahartiala T, Sorsa T, Larmas M, Salo T, Tjäderhane L. Matrix metalloproteinase-8 (MMP-8) is the major collagenase in human dentin. Arch Oral Biol 2007;52:121- 127.
  • 48. Keltjens HM, Schaeken MJ, Van Der Hoeven JS, Hendriks JC. Microflora of plaque from sound and carious root surfaces. Caries Res 1987;21:193-199.
  • 49. Jackson RJ, Lim DV, Dao ML. Identification and analysis of a collagenolytic activity in Streptococcus mutans. Curr Microbiol 1997;34:49-54.
  • 50. Okada Y, Naka K, Kawamura K, Matsumoto T, Nakanishi I, Fujimoto N, Sato H, Seiki M. Localization of matrix metalloproteinase 9 (92-kilodalton gelatinase/type IV collagenase_/ gelatinase B) in osteoclasts: implications for bone resorption. Lab Invest 1995;72:311-322.
  • 51. Kawasaki K, Featherstone JDB. Effects of collagenase on root demineralization. J Dent Res 1997;76: 588-595.
  • 52. Pashley DH, Tay FR, Yiu C, Hashimoto M, Carvalho RM, Ito S. Collagen degradation by host-derived enzymes during aging. J Dent Res 2004;83:216-221.
  • 53. Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996;23:1127-1132.
  • 54. Vuotila T, Ylikontiola L, Sorsa T, Luoto H, Hanemaaijer R, Salo T, Tjäderhane L. The relationship between MMPs and pH in whole saliva of irradiated head and neck cancer patients. J Oral Pathol Med 2002;31:329-338.
  • 55. Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, Xu JW, Manthorpe R, Whittington J, Larsson A, Salo T, Kjeldsen L, Stenman UH, Eisen AZ. Matrix metalloproteinase (MMP)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren’s syndrome. Matrix Biol 1998;17:/335-347.
  • 56. Lauhio A, Salo T, Tjäderhane L, Lahdevirta J, Golub LM, Sorsa T. Tetracyclines in treatment of rheumatoid arthritis. Lancet 1995;346:645-646.
  • 57. Sulkala M, Wahlgren J, Larmas M, Sorsa T, Teronen O, Salo T, Tjäderhane L. The effects of MMP inhibitors on human salivary MMP activity and caries progression in rats. J Dent Res 2001; 80: 1545-1549.
  • 58. Gendron R, Greiner D, Sorsa T, Maryrand D. Inhibition of the activities of matrix metalloproteinases 2, 8 and 9 by chlorexidine. Clin Diagn Lab Immunol 1999;6:437-439.
  • 59. Van Strijp AJP, Jansen DC, Degroot J, Ten Cate JM, Everts V. Host-derived proteinases and degradation of dentin collagen in situ. Caries Res 2003;37:58-65.
  • 60. De Munck J, Van Meerbeek B, Yoshida Y, Inoue S, Vargas M, Suzuki K, Lambrechts P, Vanherle G. Four-year water degradation of total etch adhesives bonded to dentin. J Dent Res 2003;82:136-140.
  • 61. Hashimoto M, Tay FR, Ohno H, Sano H, Kaga M, Yiu C, Kumagai H, Kudou Y, Kubota M, Oguchi H. SEM and TEM analysis of water degradation of human dentinal collagen. J Biomed Mater Res 2003;66:287-298.
  • 62. Carrilho MRO, Tay FR, Pashley DH, Tjäderhane L, Carvalho RM. Mechanical stability of resin-dentin bond components. Dent Mater 2005;21:232-241.
  • 63. Hebling J, Pashley DH, Tjaderhane L, Tay FR. Chlorhexidine arrests subclinical degradation of dentin hybrid layers in vivo. J Dent Res 2005;84:741-746.
  • 64. Van Meerbeek B, De Munck J, Yoshida Y, Inoue S, Vargas M, Vijay P, Van Landuyt K, Lambrechts P, Vanherle G. Buonocore memorial lecture. Adhesion to enamel and dentin: current status and future challenges. Oper Dent 2003;28:215- 235.
  • 65. De Munck J, Van Landuyt K, Peumans M, Poitevin A, Lambrechts P, Braem M, Van Meerbeek B. A critical review of the durability of adhesion to tooth tissue: methods and results. J Dent Res 2005;84:118-132.
  • 66. Breschi L, Mazzoni A, Ruggeri A, Cadenaro M, Di Lenarda R, De Stefano Dorigo E. Dental adhesion review: aging and stability of the bonded interface. Dent Mater 2008;24:90-101.
  • 67. Tay FR, Pashley DH, Loushine RJ, Weller RN, Monticelli F, Osorio R. Self-etching adhesives increase collagenolytic activity in radicular dentin. J Endod 2006;32:862-868.
  • 68. Carrilho MR, Geraldeli S, Tay F, de Goes MF, Carvalho RM, Tjäderhane L, Reis AF, Hebling J, Mazzoni A, Breschi L, Pashley D. In vivo preservation of the hybrid layer by chlorhexidine. J Dent Res 2007;86:529-533.
  • 69. Koshiro K, Inoue S, Tanaka T, Koase K, Fujita M, Hashimoto M, Sano H. In vivo degradation of resin-dentin bonds produced by a self-etch vs. a total-etch adhesive system. Eur J Oral Sci 2004;112:368-375.
  • 70. Mazzoni A, Pashley DH, Nishitani Y, Breschi L, Mannello F, Tjäderhane L, Toledano M, Pashley EL, Tay FR. Reactivation of inactivated endogenous proteolytic activities in phosphoric acid-etched dentine by etch-and-rinse adhesives. Biomaterials 2006;27:4470-4476.
  • 71. Nishitani Y, Yoshiyama M, Wadgaonkar B, Breschi L, Mannello F, Mazzoni A, Carvalho RM, Tjäderhane L, Tay FR, Pashley DH. Activation of gelatinolytic/ collagenolytic activity in dentin by self-etching adhesives. Eur J Oral Sci 2006;114:160-166.
  • 72. Mazzoni A, Mannello F, Tay FR, Tonti GAM, Papa S, Mazotti G, Di Lenarda R, Pashley DH, Breschi L. Zymographic analysis and characterization of MMP-2 and -9 forms in human sound dentin. J Dent Res 2007;86:436-440.
  • 73. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997;75:69-75.
  • 74. Overall CM, Lopez-Otín C. Strategies for MMP inhibition in cancer: innovations for the posttrial era. Nat Rev Cancer 2002;2:657-672.
  • 75. Santos M, De Souza A, Gerlach R, Trevılatto P, Scarel-Camınaga R, Lıne S. Inhibition of human pulpal gelatinases (MMP-2 and MMP-9) by zinc oxide cements. J Oral Rehabil 2004;31;660–664.
  • 76. Ramamurthy NS, Rifkin BR, Greenwald RA, Xu JW, Liu Y, Turner G, Golub ML, Vernillo AT. Inhibition of matrix metalloproteinase-mediated periodontal bone loss in rats: a comparison of 6 chemically modified tetracyclines. J Periodontol 2002;73:726-734.
  • 77. Kivela-Rajamaki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa V, Salo T, Sorsa T. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8 (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodontal Res 2003;38:583-590
  • 78. Golub LM, Lee HM, Ryan ME, Giannobile WV, Payne J, Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple nonantimicrobial mechanisms. Adv Dent Res 1998;12:12-26.
  • 79. Tjäderhane L, Sulkala M, Sorsa T, Teronen O, Larmas M, Salo T. The effect of MMP inhibitor metastat on fissure caries progression in rats. Ann NY Acad Sci 1999;878:686-688.
  • 80. Huet E, Cauchard JH, Berton A, Robinet A, Decarme M, Hornebeck W, Bellon G. Inhibition of plasminmediated prostromelysin-1 activation by interaction of long chain unsaturated fatty acids with kringle 5. Biochem Pharmacol 2004;67:643-654.
  • 81. Demeule M, Brossard M, Page M, Gingras D, Beliveau R. Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 2000;1478:51-60.
  • 82. Garbisa S, Sartor L, Biggin S, Salvato B, Benelli R, Albini A. Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer 2001;91:822-832.
  • 83. Sartor L, Pezzato E, Dell'Aica I, Caniato R, Biggin S, Garbisa S. Inhibition of matrix-proteases by polyphenols: chemical insights for anti-inflammatory and anti-invasion drug design. Biochem Pharmacol 2002;64:229-237.
  • 84. Stanley A, Wilson M, Newman HN. The in vitro effects of chlorhexidine on subgingival plaque bacteria. J Clin Periodontol 1989;16:259–264.
  • 85. Jolkovsky DL, Waki MY, Newman MG, Otomo-Corgel J, Madison M, Flemming TF, Nachnani S, Nowzari H. Clinical and microbiological effects of subgingival and gingival marginal irrigation with chlorhexidine gluconate. J Periodontol 1990;61:663– 669.
  • 86. Wieder, SG, Newman HN, Strahan JD. Stannous fluoride and subgingival chlorhexidine irrigation in the control of plaque and chronic periodontitis. J Clin Periodontol 1983;10:172–181.
  • 87. Lee W, Aitken S, Sodek J, McCulloch C. Evidence of a direct relationship between neutrophil collagenase activity and periodontal tissue destruction in vivo: a role of active enzyme in human periodontitis. J Periodontal Res 1995;30:23–33.
  • 88. Rifkin, BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissuedestructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. J Periodontol 1993;64:819–827.
  • 89. Hashimoto M, Ohno H, Sano H, Kaga M, Oguchi H. In vitro degradation of resin-dentin bonds analyzed by microtensile bond test, scanning and transmission electron microscopy. Biomaterials 2003;24:3795-3805.
  • 90. Ferrari M, Mason PN, Goracci C, Pashley DH, Tay FR. Collagen degradation in endodontically treated teeth after clinical function. J Dent Res 2004;83:414-419.
  • 91. Yoshida E, Hashimoto M, Hori M, Kaga M, Sano H, Oguchi H. Deproteinizing effects on resin-tooth bond structures. J Biomed Mater Res B Appl Biomater 2004;68:29-35.
  • 92. Armstrong SR, Vargas MA, Chung I, Pashley DH, Campbell JA, Laffoon JE, Qian F. Resin-dentin interfacial ultrastructure and microtensile dentin bond strength after five-year water storage. Oper Dent 2004;29:705-712.
There are 92 citations in total.

Details

Primary Language Turkish
Journal Section Review
Authors

Hande Erkli

Engin Ersöz

Publication Date September 23, 2011
Submission Date October 22, 2010
Published in Issue Year 2011Volume: 14 Issue: 3

Cite

EndNote Erkli H, Ersöz E (September 1, 2011) Matriks metalloproteinazlar: diş dokuları ve çürük üzerine etkileri. Cumhuriyet Dental Journal 14 3 246–257.

Cumhuriyet Dental Journal (Cumhuriyet Dent J, CDJ) is the official publication of Cumhuriyet University Faculty of Dentistry. CDJ is an international journal dedicated to the latest advancement of dentistry. The aim of this journal is to provide a platform for scientists and academicians all over the world to promote, share, and discuss various new issues and developments in different areas of dentistry. First issue of the Journal of Cumhuriyet University Faculty of Dentistry was published in 1998. In 2010, journal's name was changed as Cumhuriyet Dental Journal. Journal’s publication language is English.


CDJ accepts articles in English. Submitting a paper to CDJ is free of charges. In addition, CDJ has not have article processing charges.

Frequency: Four times a year (March, June, September, and December)

IMPORTANT NOTICE

All users of Cumhuriyet Dental Journal should visit to their user's home page through the "https://dergipark.org.tr/tr/user" " or "https://dergipark.org.tr/en/user" links to update their incomplete information shown in blue or yellow warnings and update their e-mail addresses and information to the DergiPark system. Otherwise, the e-mails from the journal will not be seen or fall into the SPAM folder. Please fill in all missing part in the relevant field.

Please visit journal's AUTHOR GUIDELINE to see revised policy and submission rules to be held since 2020.